Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT07773363 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

NCT07773363 · ClinicalTrials.gov record · last posted 2026-08-19

Retlirafusp Alfa Plus Apatinib and Chemotherapy as Second-Line Treatment for Pancreatic Cancer

Name: Retlirafusp Alfa Plus Apatinib and Chemotherapy as Second-Line Treatment for Pancreatic Cancer — clinical trial record (NCT07773363)
Creator: DataLookout
License: https://creativecommons.org/licenses/by/4.0/

StatusNot Yet Recruiting

PhasePhase 2

SponsorTang-Du Hospital

Started2026-08-30

View on ClinicalTrials.gov ↗

from the ClinicalTrials.gov record

This is a prospective, open-label, single-arm clinical study designed to evaluate the efficacy and safety of retlirafusp alfa combined with apatinib and chemotherapy as second-line treatment in patients with unresectable locally advanced or metastatic pancreatic cancer who have experienced disease progression after first-line systemic therapy. Approximately 37 participants will be enrolled. The primary endpoint is progression-free survival (PFS). Secondary endpoints include overall survival (OS), objective response rate (ORR), disease control rate (DCR), duration of response (DOR), and safety.

Trial Details

NCT Number	NCT07773363
Lead Sponsor	Tang-Du Hospital
Conditions	Pancreatic Cancer
Enrollment	37 participants
Start Date	2026-08-30
Primary Completion	2027-12-30 (estimated)
Study Completion	2028-12-30 (estimated)
Updated on ClinicalTrials.gov	2026-08-19